Among High Responders, is Oocyte Development Potential Different in Rotterdam Consensus PCOS Vs Non-PCOS Patients Undergoing IVF?

Overview

Journal J Assist Reprod Genet

Publisher Springer

Specialties Genetics
Reproductive Medicine

Date 2022 Aug 27

PMID 36029372

Authors

Veronique Bellemare

Keren Rotshenker-Olshinka

Laura Nicholls

Alyson Digby

Amrita Pooni

Einav Kadour-Peero

Weon-Young Son

Michael H Dahan

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the oocyte potential to develop to blastocyst in Rotterdam consensus PCOS in women with hyper-responses requiring freeze-all embryos.

Methods: Retrospective, single-academic center, cohort study of 205 patients who underwent freeze-all antagonist IVF cycles for OHSS risk between 2013 and 2019. Women in the PCOS group (n = 88) were diagnosed per the 2003 Rotterdam criteria. Control patients (n = 122) had no evidence of hyperandrogenism or menstrual disturbance. Data was compared by t-tests, chi-squared tests, or multivariate logistic regression (SPSS). Frozen blastocysts were Gardner's grade BB or better.

Results: There was no difference in terms of number of oocytes collected (PCOS vs non-PCOS 27.7 ± 9.4 vs 25.9 ± 8.2, p = 0.157), number of MII (20.7 ± 8.0 vs 19.1 ± 6.6, p = 0.130), number of 2PN fertilized (15.6 ± 7.4 vs 14.4 ± 5.9, p = 0.220), and number of frozen blastocysts (7.8 ± 4.9 vs 7.1 ± 3.8, p = 0.272). In addition, fertilization rates (74 ± 17% vs 75 ± 17%, p = 0.730), blastulation rates per 2PN (51 ± 25% vs 51 ± 25%, p = 0.869), and blastulation rates per mature oocytes (37 ± 18% vs 37 ± 15%, p = 0.984) were all comparable between PCOS and controls, respectively. Moreover, there was no difference when comparing PCOS and controls in pregnancy rates (45/81 vs 77/122, p = 0.28) and clinical pregnancy rates (34/81 vs 54/122, p = 0.75), respectively. Multivariate logistic regression controlling for confounders failed to alter these results.

Conclusion: PCOS subjects do not seem to have altered oocyte potential as measured by number of MII oocytes collected, fertilization, and blastulation rates when compared to high-responder controls, with similar magnitude of stimulation.

References

Ashkenazi J, Farhi J, Orvieto R, Homburg R, Dekel A, Feldberg D . Polycystic ovary syndrome patients as oocyte donors: the effect of ovarian stimulation protocol on the implantation rate of the recipient. Fertil Steril. 1995; 64(3):564-7. DOI: 10.1016/s0015-0282(16)57793-0. View

Pellicer A, Valbuena D, Cano F, Remohi J, Simon C . Lower implantation rates in high responders: evidence for an altered endocrine milieu during the preimplantation period. Fertil Steril. 1996; 65(6):1190-5. DOI: 10.1016/s0015-0282(16)58337-x. View

Plachot M, Belaisch-Allart J, Mayenga J, Chouraqui A, Tesquier A, Serkine A . [Oocyte and embryo quality in polycystic ovary syndrome]. Gynecol Obstet Fertil. 2003; 31(4):350-4. DOI: 10.1016/s1297-9589(03)00059-6. View

Urman B, Tiras B, Yakin K . Assisted reproduction in the treatment of polycystic ovarian syndrome. Reprod Biomed Online. 2004; 8(4):419-30. DOI: 10.1016/s1472-6483(10)60926-1. View

Kdous M, Chaker A, Zhioua A, Zhioua F . [Oocyte and embryo quality and outcome of ICSI cycles in patients with polycystic ovary syndrome (PCOS) versus normo-ovulatory]. J Gynecol Obstet Biol Reprod (Paris). 2009; 38(2):133-43. DOI: 10.1016/j.jgyn.2008.12.001. View

Sengoku K, Tamate K, Takuma N, Yoshida T, Goishi K, Ishikawa M . The chromosomal normality of unfertilized oocytes from patients with polycystic ovarian syndrome. Hum Reprod. 1997; 12(3):474-7. DOI: 10.1093/humrep/12.3.474. View

Aboulghar M, Mansour R, Serour G, Ramzy A, Amin Y . Oocyte quality in patients with severe ovarian hyperstimulation syndrome. Fertil Steril. 1998; 68(6):1017-21. DOI: 10.1016/s0015-0282(97)00409-3. View

Hardy K, ROBINSON F, Paraschos T, Wicks R, Franks S, Winston R . Normal development and metabolic activity of preimplantation embryos in vitro from patients with polycystic ovaries. Hum Reprod. 1995; 10(8):2125-35. DOI: 10.1093/oxfordjournals.humrep.a136247. View

Teede H, Misso M, Costello M, Dokras A, Laven J, Moran L . Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018; 33(9):1602-1618. PMC: 6112576. DOI: 10.1093/humrep/dey256. View

10.

Patel K, Coffler M, Dahan M, Malcom P, Deutsch R, Chang R . Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2003; 60(1):67-74. DOI: 10.1111/j.1365-2265.2004.01945.x. View

11.

Tang K, Wu L, Luo Y, Gong B . In vitro fertilization outcomes in women with polycystic ovary syndrome: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021; 259:146-152. DOI: 10.1016/j.ejogrb.2021.02.023. View

12.

Rienzi L, Balaban B, Ebner T, Mandelbaum J . The oocyte. Hum Reprod. 2012; 27 Suppl 1:i2-21. DOI: 10.1093/humrep/des200. View

13.

Teede H, Deeks A, Moran L . Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010; 8:41. PMC: 2909929. DOI: 10.1186/1741-7015-8-41. View

14.

Qiao J, Feng H . Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update. 2010; 17(1):17-33. PMC: 3001338. DOI: 10.1093/humupd/dmq032. View

15.

Patel K, Coffler M, Dahan M, Yoo R, Lawson M, Malcom P . Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion. J Clin Endocrinol Metab. 2003; 88(11):5456-61. DOI: 10.1210/jc.2003-030816. View

16.

Dor J, Shulman A, Levran D, Ben-Rafael Z, Rudak E, Mashiach S . The treatment of patients with polycystic ovarian syndrome by in-vitro fertilization and embryo transfer: a comparison of results with those of patients with tubal infertility. Hum Reprod. 1990; 5(7):816-8. DOI: 10.1093/oxfordjournals.humrep.a137189. View

17.

Ludwig M, Finas D, Al-Hasani S, Diedrich K, Ortmann O . Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients. Hum Reprod. 1999; 14(2):354-8. DOI: 10.1093/humrep/14.2.354. View

18.

Sharara F, McClamrock H . High estradiol levels and high oocyte yield are not detrimental to in vitro fertilization outcome. Fertil Steril. 1999; 72(3):401-5. View

19.

Adashi E . The IGF family and folliculogenesis. J Reprod Immunol. 1998; 39(1-2):13-9. DOI: 10.1016/s0165-0378(98)00026-6. View

20.

Sahu B, Ozturk O, Ranierri M, Serhal P . Comparison of oocyte quality and intracytoplasmic sperm injection outcome in women with isolated polycystic ovaries or polycystic ovarian syndrome. Arch Gynecol Obstet. 2007; 277(3):239-44. DOI: 10.1007/s00404-007-0462-x. View